CANCER DRUGS: Smart Weapons Prove Tough to Design

doi:10.1126/science.298.5593.522

Account Information

Guest Alerts | Access Rights | My Account | Sign In

Site Navigation

Article Views

Article Tools

My Science

More Information

Related Jobs from ScienceCareers

Science 18 October 2002:
Vol. 298. no. 5593, pp. 522 - 525
DOI: 10.1126/science.298.5593.522

Prev | Table of Contents | Next

News Focus

CANCER DRUGS:
Smart Weapons Prove Tough to Design

Jennifer Couzin

Data from several clinical trials of Iressa, an experimental drug in a new class of targeted cancer therapies, have been inconsistent, and some have been flatly disappointing. Even so, on 24 September, the U.S. Food and Drug Administration's Oncology Drug Advisory Committee voted 11 to 3 to recommend that the agency approve the drug to treat a common form of lung cancer, known as non-small-cell lung cancer. The agency now has less than 6 months to decide whether to allow Iressa on the market, and the lobbying has been intense.

Read the Full Text

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:

PIK3CA Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma of the Pancreas..: F. Schonleben, W. Qiu, N. T. Ciau, D. J. Ho, X. Li, J. D. Allendorf, H. E. Remotti, and G. H. Su (2006)
Clin. Cancer Res. 12, 3851-3855
| Abstract » | Full Text » | PDF »

PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.: W. Qiu, F. Schonleben, X. Li, D. J. Ho, L. G. Close, S. Manolidis, B. P. Bennett, and G. H. Su (2006)
Clin. Cancer Res. 12, 1441-1446
| Abstract » | Full Text » | PDF »

Telomere-based DNA damage responses: a new approach to melanoma.: N. PURI, M. S. ELLER, H. R. BYERS, S. DYKSTRA, J. KUBERA, and B. A. GILCHREST (2004)
FASEB J 18, 1373-1381
| Abstract » | Full Text » | PDF »

To Advertise | Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)

You have reached the bottom of the page. Back to top

Site Tools

Site Search

Account Information